There are a number of proteomic-based profiling techniques which have emerged as enabling platforms for use in all aspects of the drug discovery process. This is critical as current diagnostic procedures and strategies for developing novel medicines are in need of a paradigm change. The regulatory health authorities now consider the incorporation of biomarkers into clinical platforms to be of critical importance for the future drug discovery and have called for efforts to modernise methods, tools and techniques to achieve this goal. Given the complex nature and low abundance of many proteomic biomarkers, this will most likely require the development of more sensitive methods and a massive integration of technologies. For example, we are developing novel applications of a high throughput cytomics platform for neuropsychiatric disorders (see Technology section).